Can Dynamic Contrast Enhanced Computed Tomography (DCE-CT) scans aid in the diagnosis of early stage lung cancer and are they cost effective?

Conditions

Diagnosis of early stage lung cancer in a population that have a single pulmonary nodule detected by conventional CT scan Cancer Malignant neoplasm of bronchus and lung

Fiona J Gilbert, Scott Harris, Kenneth A Miles, Jonathan R Weir-McCall, Nagmi R Qureshi et al. (37 authors)

Health Technology Assessment2022-03-015 citations

10.3310/wcei8321

Impact of solitary pulmonary nodule size on qualitative and quantitative assessment using 18F-fluorodeoxyglucose PET/CT: the SPUTNIK trial.

Weir-McCall JR, Harris S, Miles KA, Qureshi NR, Rintoul RC, Dizdarevic S, Pike L, Cheow HK, Gilbert FJ, SPUtNIk investigators.

2020-11-0113 citations

10.1007/s00259-020-05089-y

Accuracy and cost-effectiveness of dynamic contrast-enhanced CT in the characterisation of solitary pulmonary nodules—the SPUtNIk study

Nagmi R. Qureshi, Robert C. Rintoul, Kenneth A. Miles, S. George, Scott Harris et al. (33 authors)

BMJ Open Respiratory Research2016-10-018 citations

10.1136/bmjresp-2016-000156

Interventions

This is a diagnostic study involving the addition of a single DCE-CT scan, performed on the same day or within 2 weeks of a FDG-PET/CT scan which is standard NHS care for patients presenting with an S

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. A soft tissue solitary dominant pulmonary nodule of = 8mm and = 30mm on axial plane, measured on lung window using conventional CT scan with no other ancillary evidence strongly indicative of malignancy (e.g. distant metastases) or unequivocal local invasion. 2. 18 years of age or over at time of providing consent 3. Able and willing to consent to study

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. History of malignancy within the past 2 years 3. Confirmed aetiology of the nodule 4. Biopsy of nodule prior to DCE-CT scan 5. Contra-indication to potential radiotherapy or surgery 6. Contra indication to scans (assessed by local procedures)

Design outcomes

Primary

Measure	Time frame
1. Diagnostic test characteristics of sensitivity, specificity and accuracy for both FDG-PET/CT and DCE-CT scans in relation to a subsequent clinical diagnosis of lung cancer. 2. Economic model will include accuracy, estimated life expectancy, and quality adjusted life years (QALYs) 3. Costs will be estimated from an NHS perspective. Incremental cost-effectiveness ratios will compare management strategies with DCE-CT to strategies without DCE-CT.	—

Measure

Time frame

1. Diagnostic test characteristics of sensitivity, specificity and accuracy for both FDG-PET/CT and DCE-CT scans in relation to a subsequent clinical diagnosis of lung cancer. 2. Economic model will include accuracy, estimated life expectancy, and quality adjusted life years (QALYs) 3. Costs will be estimated from an NHS perspective. Incremental cost-effectiveness ratios will compare management strategies with DCE-CT to strategies without DCE-CT.

—

Secondary

Measure	Time frame
1. Diagnostic test characteristics for FDG-PET/CT with incorporation of CT appearances and combined DCE-CT/FDG-PET scans. 2. Incidence of incidental extra-thoracic findings on FDG-PET/CT and subsequent investigations and costs will also be determined.	—

Countries

England, United Kingdom

Outcome results

None listed